PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia
Research article published in Transfusion (2025)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a severe complication characterized by thrombocytopenia and thrombosis. The presence of antibodies against heparin/platelet factor 4 (PF4) complexes is a key indicator for HIT. Diagnostic laboratory testing generally includes detection of anti-heparin/PF4 and/or functional testing such as the heparin-induced platelet activation assay (HIPAA). However, current functional tests are time-consuming and require specific technical skills. The PF4-dependent P-selectin expression assay (PEA) is a flow cytometry-based test that evaluates activation of donor platelets in the presence of HIT patient serum. METHODS: We conducted the PEA with 23 patient sera that were positive in both the anti-PF4/heparin enzyme-linked immunosorbent assay (ELISA) and HIPAA and 26 sera that tested negative in the anti-PF4/heparin ELISA. We next compared the PEA to the HIPAA using a retrospective clinical cohort of 195 sera of suspected HIT patients and tested the reproducibility of the PEA. RESULTS: The PEA was found to have a sensitivity of 73.9% and a specificity of 73.1% compared to the HIPAA. In our retrospective clinical cohort, we found that 74.4% (145 out of 195 samples) had identical results in both the HIPAA and PEA, with a specificity of 64.94% and sensitivity of 80.51% for the PEA compared to the HIPAA. Reproducibility testing of the PEA across three independent runs demonstrated consistent results in 83.3% (30 out of 36 samples). DISCUSSION: These findings suggest that the PEA is a promising functional test for HIT laboratory diagnostics based on the relatively high sensitivity; however, further studies are needed to validate its clinical applicability.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
In 195 sera from suspected HIT patients, a flow-cytometric PF4-dependent P-selectin expression assay agreed with the heparin-induced platelet activation assay in 74.4% of samples, showing 80.51% sensitivity and 64.94% specificity, with consistent results in 83.3% of reproducibility runs.
Why This Matters for Hirudotherapy
This diagnostic-accuracy study compared a flow-cytometry PF4-dependent P-selectin expression assay (PEA) against the established heparin-induced platelet activation assay (HIPAA) for diagnosing heparin-induced thrombocytopenia, reporting in a retrospective cohort of 195 suspected-HIT sera that the two tests agreed in 74.4% of samples, with the PEA showing 80.51% sensitivity and 64.94% specificity versus HIPAA, and the authors concluding it is a promising but not-yet-validated functional test. For hirudotherapy this is background to the HIT field: better, faster HIT diagnosis matters precisely because confirmed HIT mandates non-heparin anticoagulation, the clinical niche that direct thrombin inhibitors such as the leech-derived hirudin were developed to fill. Caveat: this is a laboratory method-comparison study against an imperfect reference standard, the authors flag the need for further validation, and it does not study leech therapy.
Citation
PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia.
Meier et al. · Transfusion, 2025
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026